A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer(mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-3;NCT06136624)
A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent in Metastatic Castration-resistant Prostate Cancer Post One NHA (OMAHA-4; NCT06136650)
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function – Renal impairment (CAAA617A12202)
Renal impairment Weiterlesen »